Medicure's 2025 Financial Results Indicate Revenue Growth Amid Losses

Medicure Inc., a Winnipeg-based pharmaceutical company, released its financial results for the year ending December 31, 2025. The company reported total net revenue of $28.9 million, an increase from $21.9 million in the previous year. However, the net loss widened to $7.1 million from $1.0 million in 2024, primarily due to a $2.1 million CMS rebate liability, increased R&D expenses, and non-cash amortization.

Revenue from AGGRASTAT® sales decreased to $5.7 million, impacted by reduced sales volume and competitive pricing. Conversely, the pharmacy division, including acquisitions Marley Drug, Gateway Medical Pharmacy, and West Olympia Pharmacy, showed robust growth. This segment recorded $20.3 million in net revenue, up from $10.8 million in 2024.

The company's expenses rose, with adjusted EBITDA at negative $1.5 million. Research investments reached $3.2 million, reflecting its commitment to innovative treatments like MC-1 for PNPO deficiency. Medicure's cash reserves decreased to $3.8 million by year-end 2025.